EMA-CO and EMA-EP chemotherapy protocols
SOGC/GOC Clinical Guideline #408, January 2021
| Protocol | Drug, dosage and route | Administration |
|---|---|---|
| EMA-CO | Etoposide 100 mg/m2 IV infusion | D1 and D2 |
| Dactinomycin 0.5 mg bolus IV | D1 and D2 | |
| Methotrexate 100 mg/m2 bolus IV | D1 | |
| Methotrexate 200 mg/m2 IV infusion | D1 | |
| Leucovorin 15 mg IM or PO q12 h. x4 | D2 and D3 | |
| Cyclophosphamide 600 mg/m2 IV infusion | D8 | |
| Vincristine 1 mg/m2 bolus IV | D8 | |
| EMA-EP | Etoposide 100 mg/m2 IV infusion | D1 and D2 |
| Dactinomycin 0.5 mg bolus IV | D1 and D2 | |
| Methotrexate 100 mg/m2 bolus IV | D1 | |
| Methotrexate 200 mg/m2 IV infusion | D1 | |
| Leucovorin 15 mg IM or PO q12 h. x4 | D2 and D3 | |
| Cisplatin 60 mg/m2 IV infusion | D8 | |
| Etoposide 100 mg/m2 IV infusion | D8 |
2021. Guideline No. 408: Management of Gestational Trophoblastic Diseases. Eiriksson L, Dean E, Sebastianelli A, Salvador S, Comeau R, Jang JH, Bouchard-Fortier G, Osborne R, Sauthier Ph. J Obstet Gynaecol Can;43(1):91-105.
Modified on 12/23/2023